CRH completes latest phase of share buyback and announces new $0.3 billion repurchase

Jim Mintern Chief Executive Officer and Executive Director CRH
Jim Mintern Chief Executive Officer and Executive Director - CRH
0Comments

CRH has completed the latest phase of its share buyback program, returning an additional $0.3 billion to shareholders. The company repurchased 3.2 million ordinary shares listed on the New York Stock Exchange between May 6, 2025 and August 5, 2025. This brings the total amount returned to shareholders under the ongoing share buyback program to $9.1 billion since it began in May 2018.

In a new development, CRH announced an agreement with BNP Paribas Securities Corp. (BNPP) to independently conduct another buyback program. Under this arrangement, up to $0.3 billion will be used to repurchase ordinary shares listed on the New York Stock Exchange on behalf of CRH. The new buyback will start on August 7, 2025 and is scheduled to end by November 5, 2025.

The maximum number of ordinary shares that may be acquired through this buyback is set at 65 million. The aim is to reduce CRH’s share capital; all repurchased shares will be cancelled and no purchases will take place outside the United States.

According to CRH, “Any decision in relation to any future buyback program will be based on an ongoing assessment of the capital needs of the business and general market conditions.”

The process for this buyback will follow safe harbor guidelines under both U.S Securities Exchange Act regulations and UK Market Abuse Regulation.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.